Cargando…
Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
BACKGROUND: Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain. METHODS: Data were pooled from two 6-month, placebo-controlled, pha...
Autores principales: | Abrao, Mauricio S., Surrey, Eric, Gordon, Keith, Snabes, Michael C., Wang, Hui, Ijacu, Horia, Taylor, Hugh S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210385/ https://www.ncbi.nlm.nih.gov/pubmed/34134684 http://dx.doi.org/10.1186/s12905-021-01385-3 |
Ejemplares similares
-
Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix
por: Agarwal, Sanjay K, et al.
Publicado: (2021) -
Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix
por: Taylor, Hugh S., et al.
Publicado: (2020) -
A Clinician's Guide to the Treatment of Endometriosis with Elagolix
por: Leyland, Nicholas, et al.
Publicado: (2021) -
Elagolix in the treatment of endometriosis: impact beyond pain
symptoms
por: Archer, David F., et al.
Publicado: (2020) -
Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
por: Surrey, Eric S, et al.
Publicado: (2020)